Skip to main content

Table 1 Comparison of demographic characteristics of survivors and non survivors of Pseudomonas aeruginosa bacteremia

From: Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy

 

Total (n = 234)

Non survivors (n = 52)

Survivors (n = 182)

Pvalue

Age, median years (range)

57 (19 ~ 93)

60.5 (19 ~ 84)

56 (21 ~ 93)

0.35

Male sex

92 (39.3%)

23 (44.2%)

69 (37.9%)

0.41

Underlying disease

 Diabetes mellitus

47 (20.1%)

8 (15.4%)

39 (21.4%)

0.34

 Hypertension

52 (22.2%)

11 (21.2%)

41 (22.5%)

0.83

 Liver cirrhosis

13 (5.6%)

2 (3.8%)

11 (6.0%)

0.54

 Transplant

34 (14.5%)

10 (19.2%)

24 (13.2%)

0.27

 Solid organ

8 (3.4%)

1 (1.9%)

7 (3.8%)

 

 Bone marrow

26 (11.1%)

9 (17.3%)

17 (9.3%)

 

 Malignancy

68 (29.1%)

14 (26.9%)

54 (29.7%)

0.70

 Dialysis

11 (4.7%)

2 (3.8%)

9 (4.9%)

0.74

Neutropenia

54 (23.1%)

18 (34.6%)

36 (19.8%)

0.02

Hospitalization in the preceding 90 days

98 (41.9%)

26 (50.0%)

72 (39.6%)

0.18

APACHE II score, median (IQR)

12 (0 ~ 40)

18 (5 ~ 40)

11 (0 ~ 28)

0.0001

Charlson comobidity index, median (IQR)

3 (0 ~ 13)

4 (1 ~ 10)

4 (0 ~ 13)

0.57

Septic shock

62 (26.7%)

28 (53.8%)

34 (18.7%)

0.0001

Invasive procedure

 Central venous catheter

97 (41.5%)

36 (69.2%)

61 (33.5%)

0.0001

 Surgical drainage

39 (16.7%)

8 (15.4%)

31 (17.0%)

0.78

 Foley catheter

50 (21.4%)

28 (53.8%)

22 (12.1%)

0.0001

 Mechanical ventilator

32 (13.7%)

20 (38.5%)

12 (6.6%)

0.0001

The length of stay before bacteremia, median days (IQR)

1 (0 ~ 92)

1 (0 ~ 28)

2.5 (0 ~ 92)

0.2

Source of bacteremia

   

0.006

 Pneumonia

70 (29.9%)

27 (51.9%)

43 (23.6%)

 

 Urinary tract

18 (7.7%)

2 (3.8%)

16 (8.8%)

 

 Vascular catheter-related

4 (1.7%)

1 (1.9%)

3 (1.6%)

 

 Intra-abdomen

42 (17.9%)

7 (13.5%)

35 (19.2%)

 

 Postoperative wound

11 (4.7%)

1 (1.9%)

10 (5.5%)

 

 Unknown

89 (38.0%)

14 (26.9%)

75 (41.2%)

 

Length of hospital stay, median days (IQR)

17 (1 ~ 364)

12 (1 ~ 364)

18 (1 ~ 92)

0.08

Carbapenem resistance

118 (50.4%)

26 (50.0%)

92 (50.5%)

0.94

Multidrug resistance

6 (2.6%)

3 (5.8%)

3 (1.6%)

0.09